HighTide's HTD1801 Shows Renoprotective Potential at ERA Congress

HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in cardiovascular–kidney–metabolic (CKM) diseases, presented new findings on the renoprotective effects of its lead candidate HTD1801 at the 63rd European Renal Association (ERA) Congress in Glasgow, UK. The data, shared via an oral presentation, highlights HTD1801's potential as a disease-modifying therapy for chronic kidney disease (CKD). HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In completed Phase III trials (SYMPHONY-1 and 2), HTD1801 significantly improved renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m², showing a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks without hyperfiltration or fluid retention. These clinical findings suggest HTD1801 may differentiate from existing therapies, potentially delaying or preventing disease progression.

The preclinical study, conducted in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, explored the mechanistic basis of HTD1801's renoprotection. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 preserved podocyte viability, inhibited apoptosis, restored expression of key structural proteins nephrin and podocin, and reduced inflammatory markers such as phosphorylated NF-kB and caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin. These findings provide the latest evidence supporting HTD1801's renoprotective potential and its ability to target fundamental pathophysiologic processes in CKD.

Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics, presented the data, stating that the convergence of clinical and preclinical evidence supports HTD1801's disease-modifying potential. The company plans to advance clinical development across CKD and related indications to provide more treatment options for patients worldwide. For more information, visit www.hightidetx.com. View the original release on www.newmediawire.com.